Status:

COMPLETED

Breastfeeding, Antiretroviral, and Nutrition Study

Lead Sponsor:

Centers for Disease Control and Prevention

Collaborating Sponsors:

University of North Carolina, Chapel Hill

Kamuzu Central Hospital

Conditions:

HIV Infections

Eligibility:

All Genders

14+ years

Phase:

PHASE3

Brief Summary

This is a comparative clinical trial among HIV-infected women and their infants to determine: 1. the benefit of nutritional supplementation given to women during breastfeeding 2. the benefit and safe...

Detailed Description

This study addresses the complex issues of HIV related maternal morbidity, mortality, and postnatal HIV transmission during breastfeeding and weaning in resource-poor countries. Objectives include ass...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Recruitment and primary eligibility criteria:
  • Age \> 14 years.
  • Ability to give informed assent or consent.
  • Evidence of HIV infection, as documented by 2 positive ELISA antibody tests; or 1 positive ELISA, and 1 Western Blot; or 2 separate concurrent rapid tests.
  • Currently pregnant (with a single or multiple fetuses).
  • Gestation \< 30 weeks at referral from 'Call to Action' Program
  • No serious current complications of pregnancy.
  • Intention to breastfeed.
  • Intention to deliver at the institution at which the study is based.
  • Not previously enrolled in this study for an earlier pregnancy.
  • Other than HIV, no active serious infection, such as tuberculosis or other potentially serious illnesses.
  • No previous use of antiretrovirals including the HIVNET 012 regimen.
  • Mother's CD4 count \> 250 cells/uL determined in the antenatal clinic.
  • Mother's ALT \< 2.5 x ULN (upper limit of normal) determined in the antenatal clinic
  • Secondary eligibility criteria and treatment assignment:
  • Mother who delivers outside of the institution at which the study is based must present with her infant to the study site within 36 hours of delivery.
  • Mother accepts nevirapine and zidovudine+lamivudine 7-day regimen for herself and her infant.
  • Infant birth weight \> 2000 g.
  • No severe congenital malformations or other condition(s) not compatible with life.
  • Based on clinical assessment, no maternal condition which would preclude the start of the study intervention.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2010

    Estimated Enrollment :

    2369 Patients enrolled

    Trial Details

    Trial ID

    NCT00164736

    Start Date

    March 1 2004

    End Date

    January 1 2010

    Last Update

    April 23 2010

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Kamuzu Central Hospital, Bottom Hospital

    Lilongwe, Malawi